JAK2 and myeloproliferative disorder: In MPN patients, JAK2 V617F mutation was most common, followed by mutations in ASXL1, MPL, and TET2. We found a concurrence among DNMT3A and NPM1 mutations and FLT3 ITD as previously reported (Fig 2) [19].